Merck Q1 2023 Report Shows Revenue Drop as COVID Treatment Sales Crash, MRK Stock Down 1%
Affected by decreased demand for Covid drug Molnupiravir, Merck has revealed decreased income figures in accordance with its Q1 2023 report. Multinational pharmaceutical big Merck & Co Inc (NYSE: MRK) has….